Abbott (NYSE: ABT) is turning to Google’s artificial intelligence expertise to leverage more glucose insights for users of the Abbott Park, Illinois–based life science giant’s Lingo biowearable. Under a multiyear agreement announced today, ongoing glucose insights from Abbott’s Lingo biowearable will combine with Google Health’s technology to provide a more comprehensive view of people’s health. […]
Technology
6 diabetes tech companies you need to know
You may already know a lot of the names that are considered leaders of the diabetes technology industry. The likes of Abbott and Dexcom are leaders in the continuous glucose monitor (CGM) space. MiniMed, Insulet and Tandem Diabetes Care are a few of the companies with a significant share in the automated insulin delivery (AID) […]
The 10 largest diabetes tech companies in the world in 2026
Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […]
Diabetes Technology Innovations Special Report — 2026
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]
Insulet slightly lowers 2026 sales growth outlook despite Q2 beats
Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates. The company previously projected total annual sales growth between 21% and 23%. However, it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth […]
Modular Medical to initiate first phase of Pivot pump launch in October
Modular Medical (Nasdaq:MODD) announced its plans to initiate the first phase of the launch of its Pivot tubeless insulin patch pump. Pivot, designed to make insulin pump therapy simpler to learn and easier to live with, features a removable, two-part design and a 3 mL reservoir, intuitive interface and flexible, wearable form factor. The system […]
Dexcom Q2 results beat expectations, lead to increased sales outlook
Dexcom (Nasdaq:DXCM) today reported second-quarter results that came in ahead of the consensus Wall Street forecast. Shares of DXCM rose 2% to $76.02 apiece after the market closed today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $249.1 million. That equals 64¢ per share on sales of $1.31 billion for the three […]
Micron Biomedical picks up $4.5M government contract for drug delivery patch
Micron Biomedical announced today that it received a $4.5 million contract from the National Institute of Allergy and Infectious Diseases (NIAID). NIAID (part of the NIH) awarded the contract to Micron to develop a dissolvable microarray medical countermeasure against radiation injury. The contract aims to enable rapid deployment of treatment for Acute Radiation Syndrome (ARS). […]
MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector
MannKind (Nasdaq:MNKD) announced today that it secured $50 million in a private placement and earned a new regulatory nod. In addition to the funding, the company — which also develops inhaled insulin technology — won FDA approval for the Furoscix ReadyFlow auto-injector. MannKind said it entered into a securities purchase agreement in connection with a […]
FDA selects Dexcom for new digital health device pilot
The FDA announced today that it selected Dexcom (Nasdaq:DXCM) as the first manufacturer for a new digital health pilot. Dexcom joins the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot. It intends to provide a device for use in delivering care expected to be covered by the Centers for Medicare & Medicaid Services […]
